Advertisement

Topics

Latest "launches study African American cancer survivors" News Stories

02:23 EDT 21st September 2018 | BioPortfolio

Here are the most relevant search results for "launches study African American cancer survivors" found in our extensive news archives from over 250 global news sources.

More Information about launches study African American cancer survivors on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about launches study African American cancer survivors for you to read. Along with our medical data and news we also list launches study African American cancer survivors Clinical Trials, which are updated daily. BioPortfolio also has a large database of launches study African American cancer survivors Companies for you to search.

Showing "launches study African American cancer survivors" News Articles 1–25 of 40,000+

Friday 21st September 2018

Receptor Tyrosine Protein Kinase ERBB 3 Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1 Pipeline Review, H2 2018 [Report Updated: 10072018] Prices from USD $3500

Receptor Tyrosine Protein Kinase ERBB 3 Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1 Pipeline Review, H2 2018SummaryAccording to the recently published report 'Receptor Tyrosine Protein Kinase ERBB 3 Pipeline Review, H2 2018'; Receptor Tyrosine Protein Kinase ERBB 3 Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase ...


Exelixis’ Partner Ipsen Announces Positive CHMP Opinion for CABOMETYX® (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma

– In the phase 3 pivotal CELESTIAL trial, CABOMETYX demonstrated a statistically significant and clinically meaningful overall survival benefit – Exelixis, Inc. (NASDAQ:EXEL) today announced that its partner Ipsen received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of...

Ipsen Receives Positive CHMP Opinion for Cabometyx® (Cabozantinib) for the Second-line Treatment of Patients with Hepatocellular Carcinoma (HCC)

Regulatory News: Ipsen (Euronext:IPN; ADR:IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), provided a positive opinion for Cabometyx® (cabozantinib) as a monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have been pre...


Eicosapantaenoic acid treatment based on the EPA/AA ratio in patients with coronary artery disease: follow-up data from the Tochigi Ryomo EPA/AA Trial in Coronary Artery Disease (TREAT-CAD) study

A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer

Thursday 20th September 2018

Innovent's PD-1 Candidate Effective Against NSCLC; Will Start Phase III Trial

Innovent Biologics of Suzhou reported that its PD-1 candidate, sintilimab, produced a 68% objective response rate in first-line patients with non-squamous non-small cell lung cancer. Sintilimab was administered in combination with pemetrexed and cisplatin in the Phase I trial. Based on the data, Innovent said it would start a 378-patient Phase III trial of the drug in the same population. Chi...

Why Wait for the New Year to Get Fit & Healthy? Start Your Better Nutrition Habits Now with an Omega Juicer Nutrition System

The holiday season can be a hectic and energy draining time of year—full of tempting, unhealthy food choices. Sugary and fatty foods are everywhere, often resulting in holiday hyper-consumption, followed by weight gain, low-energy AND New Year’s resolutions to improve health and wellness. Why wait for New Year’s to get healthy? Why not start good hab...

New cell-culture platform enables @HokkaidoUni researchers to observe never-before-seen behaviors of live #Cancer cells under the microscope: http://ow.ly/RgQE30lTV8A 

New cell-culture platform enables @HokkaidoUni researchers to observe never-before-seen behaviors of live #Cancer cells under the microscope: http://ow.ly/RgQE30lTV8A 

The impact of fluid balance on outcomes in critically ill near-term/term neonates: a report from the AWAKEN study group

An exploratory study by DMET array identifies a germline signature associated with imatinib response in gastrointestinal stromal tumor

“This is an important study that’s shining a light on something that we need to spend more time on.” https://buff.ly/2O4mDog 

“This is an important study that’s shining a light on something that we need to spend more time on.” https://buff.ly/2O4mDog 

Risk of premature death from chronic conditions higher in UK than many other rich countries

People in the UK have a greater risk of dying early from chronic conditions such as cancer, cardiovascular disease, chronic respiratory disease, and diabetes than those in many other high income...

High gluten diet in pregnancy linked to higher child diabetes risk

A high gluten intake by mothers during pregnancy is associated with an increased risk of their child developing type 1 diabetes, suggests a study by Danish researchers.

Wharton Alumni True Impact Focus and Wharton WISE Case Study on Real Estate Impact Investments

PRINCETON, N.J., Sept. 20, 2018 /PRNewswire/ -- Real estate investments in targeted urban and rural communities in the United States are increasingly seen as attractive Read more...

NADPH oxidase 4 regulates anoikis resistance of gastric cancer cells through the generation of reactive oxygen species and the induction of EGFR

RIF1 promotes tumor growth and cancer stem cell-like traits in NSCLC by protein phosphatase 1-mediated activation of Wnt/β-catenin signaling

CPEB1 mediates hepatocellular carcinoma cancer stemness and chemoresistance

Loss of mdig expression enhances DNA and histone methylation and metastasis of aggressive breast cancer

Author Correction: Comparison of Image-Guided Intensity-Modulated Radiotherapy and Low-dose Rate Brachytherapy with or without External Beam Radiotherapy in Patients with Localized Prostate Cancer

Novel Therapeutic Approaches for Treatment of Cancer, 2018 Report – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Novel Therapeutic Approaches for Treatment of Cancer” report has been added to ResearchAndMarkets.com’s offering. This Genetic Technology TOE depicts new life sciences trends across cancer treatment. Innovations related to the development of novel therapeutic approaches for the treatment … Continue reading → Cet article Novel Th...

Sloan Kettering’s Cozy Deal With Start-Up Ignites a New Uproar

A for-profit venture with exclusive rights to use the center’s vast archive of tissue slides has generated concerns at the nonprofit cancer center.

Global Optical Imaging Market 2017-2021 | Imaging Systems Dominates the Global Market | Technavio

According to the market research report released by Technavio, the global optical imaging market is expected to accelerate at a CAGR of more than 8% during the forecast period. The increasing market penetration of digital technologies is one of the key factors triggering the growth of the market. This press release features multimedia. View the full release...

Memorial Sloan Kettering is in turmoil over a deal officials made to share cancer patient data with a for-profit artificial intelligence start-up https://nyti.ms/2DdGVXY 

Memorial Sloan Kettering is in turmoil over a deal officials made to share cancer patient data with a for-profit artificial intelligence start-up https://nyti.ms/2DdGVXY 

American Health Quality Association’s (AHQA) QIN-QIOs are Pivotal in Reducing Costs for Medicare and Improving Health Quality, 2017 CMS Progress Report Reveals

2017 CMS Progress Report reveals that QIN-QIOs are improving health quality and reducing costs to Medicare. MCLEAN, Va. (PRWEB) September 20, 2018 In a report released earlier this month, 2017 QIO Program Progress Report, the Centers for Medicare & Medicaid Services (CMS) revealed Quality Improvement Networks-Quality Improvement Organizations (QIN-QIOs) to be the most effective “Boots on th...

TransEnterix to Participate in Two Upcoming Healthcare Conferences

TransEnterix, Inc. (NYSE American:TRXC) announced today that TransEnterix will participate in two upcoming healthcare conferences: Todd M. Pope, President and Chief Executive Officer will present at the 2018 Cantor Global Healthcare Conference at The Intercontinental New York Barclay Hotel, New York. The presentation is scheduled to ...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks